Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Gynaecological Malignancies

Presenters

Kosei Hasegawa

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

K. Hasegawa1, D. Shintani2, S. Suzuki3, K. Oda4, M. Yunokawa5, K. Yonemori6, M. Mori7, A. Kurosaki2, M. Mori8, S. Kitano9, A. Ogasawara2, Y. Saigusa10, H. Matsushita11, T. Misumi12

Author affiliations

  • 1 Gynecologic Oncology Department, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 2 Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 3 Department Of Gynecologic Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Clinical Genomics, The University of Tokyo Hospital, 113-8655 - Bunkyo-ku/JP
  • 5 Department Of Gynecology, The Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 6 Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Chuo-ku/JP
  • 7 Department Of Gynecologic Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya, Aichi/JP
  • 8 Obstetrics And Gynecology, The University of Tokyo, 153-8904 - Meguro-ku/JP
  • 9 Advanced Medical Development Center, The Cancer Institute Hospital of JFCR, 135-8550 - Koto-ku/JP
  • 10 9) department Of Biostatistics, Yokohama City University School of Medicine, 236-0004 - Yokohama/JP
  • 11 8) division Of Translational Oncoimmunology, Aichi Cancer Center Research Institute, 464-8681 - Nagoya/JP
  • 12 Department Of Biostatistics, Yokohama City University School of Medicine, 236-0004 - Yokohama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 726P

Background

Patients with recurrent cervical cancer, especially those resistant to platinum-based chemotherapy, have limited treatment options. PD-1 blockade monotherapy stands out as one of the optimal choices in this context. PARP inhibition may exert an immune modulatory effect through the cGAS/STING pathway, and this phase II trial aims to explore the efficacy and safety of pembrolizumab (Pem) plus olaparib (Ola) in this patient cohort.

Methods

This multicenter investigator-initiated single-arm Phase II trial assesses the antitumor effects and survival outcomes of combining PD-1 inhibition with Pem and PARP inhibition with Ola. Eligible patients, who had prior platinum-based chemotherapies and no prior immunotherapy, received Pem (200mg every 3 weeks) and Ola (600mg per day) combination therapy until disease progression or unacceptable toxicity. The primary endpoint is objective response rate (ORR) by RECISTv1.1.

Results

Between June 2021 and July 2022, twenty-eight patients were enrolled. Patient characteristics included a median age of 55 years, with 14 (50%) patients having squamous cell carcinoma and 14 (50%) adenocarcinoma/adenosquamous carcinoma. Twenty-two (79%) patients had more than 2 lines of chemotherapy, and 22 (79%) patients had a history of bevacizumab. Twenty-six of 28 patients were evaluable for antitumor activity, as two patients did not have RECIST evaluation after treatment initiation. The ORR was 7.7% and the disease control rate was 53.8%. The median PFS and OS were 3.4 and 11.9 months, respectively. No patients required Pem discontinuation, but 4 (14%) patients required Ola discontinuation due to adverse events (AEs). All patients and 21 (75%) patients experienced any grade of AEs due to Ola or Pem, respectively. Grade≥3 AEs were observed in 17 (61%) patients, with anemia (29%) and decreased white blood cell counts (11%) being the most common.

Conclusions

This trial investigates Pem plus Ola combination therapy in platinum-experienced recurrent cervical cancer, revealing manageable safety. However, limited activity was observed with the addition of Ola to PD-1 inhibition in this study.

Clinical trial identification

NCT04641728. First posted November 24, 2020.

Editorial acknowledgement

Legal entity responsible for the study

Gynecologic Oncology Trial and Investigation Consortium (GOTIC).

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.